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The Yin and the Yang of Keratin 
Amino Acid Substitutions and 
epidermolysis Bullosa Simplex
Dedee F. Murrell1,2, Niken Trisnowati1,2,3, Spiros Miyakis2,4  
and Amy S. Paller5
Mutations that change the same amino acid can result in different clinical 
phenotypes. Through in silico modeling and keratin filament assessment of 
genetically engineered HaCaT cells, natsuga et al., as reported in this issue, 
have demonstrated how changes in charge and structure of a replacement 
amino acid in keratin 14 can cause disease (KRT14pA413P, eB simplex) or no 
clinical effect (KRT14pA413T, polymorphism).
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epidermolysis bullosa simplex  
and keratin gene mutations
Keratin 14 is an essential filament pro­
tein of basal keratinocytes, in which it 
pairs with keratin 5 to provide structur­
al integrity and other critical functions. 
Mutations in keratin 14 lead to epi­
dermolysis bullosa simplex (EBS), a 
predominantly autosomal dominant 
disorder of skin fragility with basal 
keratinocyte lysis (Coulombe et al., 
1991). The severity of EBS ranges from 
mild blistering of the palms and soles 
(EBS, localized) to generalized skin 
blistering (EBS–generalized, other) to 
severe, generalized blistering with 
mucosal and nail involvement (EBS–
Dowling­Meara). Interestingly, most 
severely affected infants with EBS–
Dowling­Meara and EBS–generalized, 
other, markedly improve by adult­
hood. Although revertant mosaicism 
has been described in EBS (Lai­Chong 
et al., 2011) and keratino cytes with 
mutant keratin are well known to have 
a selective disadvantage, the reason for 
the marked improvement with advanc­
ing age remains unclear.
In general, more severe disease has 
been associated with mutations in more 
highly conserved α­helical rod domains 
and greater keratin aggregation in basal 
keratinocytes. In contrast, milder EBS 
exhibits relatively normal­appearing 
keratin tonofilaments ultrastructurally 
and has been linked to mutations in 
less essential central rod domains in the 
L12 nonhelical linker region and the 
H1 (head) region in KRT5.
It was subsequently recognized that 
the nature of the amino acid substitu­
tion at particular keratin gene residues 
may also profoundly affect the clini­
cal phenotype of EBS (Cummins et al., 
2001). The charge of the amino acid, 
which affects its interactions and pro­
tein secondary structure, is important. 
For example, the highly conserved 
keratin 14 methionine at position 119 
in exon 1 is hydrophobic and nonpo­
lar. When it is mutated to a hydrophilic 
and polar amino acid threonine (KRT14 
M119T), severe EBS–Dowling­Meara 
results. In contrast, when mutated 
to the hydrophobic and polar valine 
(KRT14 M119V), the outcome is 
EBS–generalized, other (Figure 1). As 
another example, mutation to arginine 
(polar, highly charged) of the methi­
onine (nonpolar, neutral) at a less con­
served linker region in KRT14 (M272) 
results in EBS–generalized, other 
(Humphries et al., 1993), whereas when 
the methionine is changed to threonine 
(polar, uncharged), it produces only 
localized EBS (DF Murrell, unpublished 
data, oral abstract, World Congress of 
Dermatology, Paris, 2002).
In this issue, Natsuga et al. dem­
onstrate another example of this 
phenomenon in an intriguing fam­
ily with variations at KRT14 A413 of 
both KRT14pA413P (leading to EBS, 
localized) and KRT14pA413T (unaf­
fected individuals). KRT14pA413 is 
a reasonably well­conserved amino 
acid among keratins (Table 1). This 
KRT14 variant A413T had previously 
been reported to be both a poly­
morphism in the Asian population 
(Hattori et al., 2006) and pathogenic 
in a Taiwanese boy with localized 
EBS (Chao et al., 2002). Indeed, our 
further sequencing of all exons of 
KRT5 and KRT14 from the Taiwanese 
case (Chao et al., 2002) confirmed 
the presence of the KRT14pA413T 
mutation but also showed a number 
of silent mutations (KRT5pD197E, 
KRT5pT198T, KRT14pN185N, and 
KRT14pE215E), all known to be sin­
gle­nucleotide polymorphisms. Given 
that the unaffected mother did not 
carry the KRT14pA413T variant and 
the unaffected father’s DNA was not 
available, the role of KRT14pA413T 
as pathogenic, either directly or 
potentially through interaction with 
KRT5 pD197E, remained unclear. The 
in silico modeling and evaluation of 
alterations of keratin tonofilaments in 
genetically engineered cells, as per­
formed by Natsuga et al. (2011, this 
issue), were not undertaken to test 
these possibilities.
Does the pathogenicity of 
Krt14pa413t depend on polymorphic 
changes in its Krt5 partner at a critical 
site of keratin 5 and 14 interaction?
The role of polymorphic gene changes 
in altering the phenotypic manifesta­
tions of gene mutations is an active area 
of investigation. Mutations in KRT14 
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table 1. nucleotide at position 413 among type I keratins and the other types of IFs
type I IFs
K9 E I E T Y H N L
K10 E I Q T Y R S L
K12 E I E T Y R R L
K13
Transcript variant 1 E I A T Y R S L
Transcript variant 2 E I A T Y R S L
K14 E I A T Y R R L
K15 E I A T Y R S L
K16 E I A T Y R R L
K17 E I A T Y R R L
K18
Transcript variant 1 E I A T Y R R L
Transcript variant 2 E I A T Y R R L
K19 E I A T Y R S L
K20 E I A T Y R R L
type III IFs
Vimentin E I A T Y R K L
type IV IFs
NF­M E I A A Y R K L
type V IFs
Lamin E I H A Y R K L
Abbreviations: IF, intermediate filament; K, keratin; NF­M, neurofilament subunit M.
The source of sequences was GenBank, with the following accession numbers: K9, NM000226; K10, NM000421; K12, NM000223; K13 transcript 
variant 1, NM153490; K13 transcript variant 2, NM002274; K14, NM000526; K15, NM002275; K16, NM005557; K17, NM000422; K18 transcript 
variant 1, NM000224; K18 transcript variant 2, NM002276; K19, NM002276; K20, NM019010; vimentin, BC000163; NF­M, Y00067; lamin, M13451. 
table 2. Glutamic acid (e) at nucleotide position 168 is highly conserved among type II keratins and the 
other types of IFs
type II IFs
K1 K S R E R E Q I K
K2e K A Q E R E Q I K
K2p K A Q E R E Q I K
K3 K A Q E R E Q I K
K4 R T E E R E Q I K
K5 R T E E R E Q I K
K6a R A E E R E Q I K
type III IFs
Vimentin S A L E K V E L Q
type IV IFs
NF­M R S N E K E Q L Q
type V IFs
Lamin R L Q E K E D L Q
Abbreviations: IF, intermediate filament; K, keratin; NF­M, neurofilament subunit M.
The source of sequences was GenBank, with the following accession numbers: K1, AF237621; K2e, AF019084; K2p, AJ564103; K3, X05418; K4, X61028; 
K5, NM000424; K6a, L42583; vimentin, BC000163; NF­M, Y00067; lamin, M13451.
commentary
 www.jidonline.org 1789
acids. The substitution of chemically 
similar amino acids, such as the sub­
stitution of glutamic acid with aspartic 
acid, is termed a synonymous or con­
servative substitution and is unlikely 
to produce much effect on protein 
structure. The difference in size of the 
substituted amino acid in a conserva­
tive substitution could influence the 
local context between keratin heterodi­
mer and lead to pathology (Liovic et al., 
2001). However, given that glutamic 
acid is larger than aspartic acid by only 
one CH2 group, it would be unlikely to 
disrupt the local context between kera­
tin heterodimers. Nevertheless, given 
the critical location of this glutamic 
acid in the KRT5 gene head domain, 
even this subtle change in size of the 
amino acid could conceivably cause 
pathology. Experiments such as those 
performed by Natsuga et al. could 
delineate whether the KRT14pA413T 
polymorphism affects the impact of 
this KRT5pE168D mutation on clinical 
phenotype.
the yin and the yang of Krt14pa413t: 
could this variant improve keratin 
stability?
The KRT14pA413T polymorphic 
variant was found by Natsuga et al. 
(2011) on one allele of two unaffected 
KRT14pA413T mutation detected using 
gDNA sequencing did not originate 
from coamplification of KRT14 pseudo­
genes. In addition, screening of 100 
Australian alleles and 100 Greek alleles 
(by SM) for either KRT14pA413T or 
KRT5pE168D showed no evidence of a 
polymorphism in these populations.
The KRT5pE168D mutation is a 
G­to­T transversion occurring in nucle­
otide 895 at residue 168 of the KRT5 
gene. This mutation results in an amino 
acid substitution from glutamic acid 
(GAG) to aspartic acid (GAT). Both glu­
tamic acid and aspartic acid are highly 
polar, negatively charged acidic amino 
and KRT5 are concentrated in four 
important regions that are predicted 
to correspond to major contact sites 
between oligomers during polymeriza­
tion of keratins (Sorensen et al., 1999). 
These sites are among the most highly 
conserved regions in intermediate fila­
ments, implying that they are impor­
tant to filament assembly. They include 
the H1 region of the KRT5 gene head 
domain, the end of the 1A segment 
(helix initiation motif), the end of the 
2B segment (helix termination motif), 
and the L12 linker region; one of these 
sites, the H1 region of KRT5, contains 
the highly conserved glutamic acid 
at residue 168 (Table 2). Two of the 
present authors (NT and DFM) par­
ticipated in a study that evaluated a 
Greek Australian family in whom the 
affected mother and daughter had 
EBS–generalized, other, and genetic 
changes in both KRT14 and KRT5 
(KRT14pA413T and a novel mutation, 
KRT5pE168D) (Trisnowati et al., 2003). 
Two unaffected family members—an 
uncle and a maternal grandmother—
also had the KRT14pA413T variant but 
no clinical disease, raising the possibili­
ties of variable disease expressivity with 
KRT14pA413T as a dominant negative 
pathogenic mutation, KRT14pA413T 
as a polymorphism, or even a recessive 
disease with no clinical manifestations 
with mutations in either KRT14pA413T 
or KRT5pE168D but an abnormal 
phenotype when genetic changes in 
both are present. The presence of the 
KRT14pA413T mutation at the RNA 
level from skin biopsies in the affected 
individuals further confirmed that the 
Figure 1. mutations in the methionine (m) at residue 119 of Krt14 in exon 1. Such mutations lead 
to either EBS–Dowling­Meara (change to threonine (T), left) or EBS–generalized, other (change to 
valine (V), right).
Clinical Implications
•  EB simplex is predominantly inherited in a dominant fashion, and, in most 
cases, a mutation is found in either the keratin 14 or the keratin 5 gene.
•  The position of the mutation affects the phenotype—mutations in the 
terminal rod domains lead to epidermolysis bullosa simplex (EBS)–
Dowling-Meara, whereas mutations in less essential linker or head 
domains largely cause EBS, localized.
•  However, the nature of the amino acid substitution in a particular 
position, particularly a highly conserved amino acid, can also affect the 
severity of the clinical phenotype of EBS.
•  Future investigations, as performed by Natsuga et al., can help to sort 
out the potential role of polymorphisms in impacting the phenotypic 
effects of keratin mutations.
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individuals, but also on both alleles 
in another unaffected individual in 
the same family. Beyond proving 
KRT14pA413T to be a nonpathogenic 
polymorphism, at least in the Asian 
population, it is intriguing to specu­
late as to why this sequence variant 
has persisted in the Asian population. 
One possibility is that the alanine­to­
threonine alteration is advantageous. 
In fact, Natsuga et al. noted less 
keratin filament aggregation in the 
HaCaT cells transfected with KRT14 
A413T than in the wild­type cells (6% 
vs. 13%, respectively), suggesting that 
there might even be a protective effect 
of having this sequence variant. The 
KRT14pA413P keratinocytes had 49% 
keratin bundling, but the possibil­
ity that the combination of the A413P 
and A413T, as existed clinically in 
the uncle, led to less keratin aggre­
gation was not tested. In addition, 
this uncle was said to be “no worse” 
than the much younger proband, but 
the authors did not report whether his 
disease was less severe, especially 
when he had been the same age as the 
proband, given the tendency toward 
improvement in EBS with advancing 
age in many patients.
The techniques used by Natsuga et 
al. to unravel the yin and yang of the 
various alterations in keratin genes and 
their impact on skin integrity could well 
be applied to address the question of 
whether KRT14pA413T might improve 
keratin stability. Furthermore, these 
types of studies should be extended 
to evaluate the impact of polymorphic 
changes in the many keratin genes that 
impact skin beyond keratins 5 and 14.
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Interpretation of Skindex-29 Scores
Francesca Sampogna1 and Damiano Abeni1
In this Commentary, we compare two categorizations of a dermatological 
health–related quality-of-life (HRQoL) instrument, the Skindex-29. One was cre-
ated on the basis of an anchor-based method, the other on a distribution-based 
method. Differences between the two classifications are discussed, emphasizing 
the importance of the interpretability of HRQoL measures.
Journal of Investigative Dermatology (2011) 131, 1790–1792. doi:10.1038/jid.2011.191
One essential property of a measure­
ment instrument is the interpretabil­
ity of its data. An understanding of the 
meaningfulness of a result is necessary 
for physicians in choosing treatments; 
for patients in understanding their con­
ditions and their changes over time; 
and for policy makers in evaluating 
relationships among benefits, adverse 
effects, and cost. In the field of health­
related quality of life (HRQoL), the 
problem of establishing meaningfulness 
is especially challenging (Guyatt et al., 
2002). Although we easily understand, 
for example, the significance of an 
increase or a decrease of one degree 
Fahrenheit or Celsius in body tempera­
ture, it is not clear how to interpret a 
five­point change in a HRQoL scale 
measurement. In this issue, Prinsen et 
al. report scores for mildly, moderately, 
and severely impaired HRQoL for the 
three subscales—emotions, symptoms, 
and functioning—of the Skindex­29 
(Chren et al., 1997). This study com­
pletes a previous study (Prinsen et al., 
2010), in which the authors identified 
cutoff points only for severely impaired 
HRQoL. To identify the categories, the 
authors used an anchor­based method 
(Lydick and Epstein, 1993) that consists 
of comparing measures of HRQoL with 
other measures or phenomena that have 
relevance to patients. In particular, they 
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